Novartis Investigative Site

Zurich, CH 8091

0 studies enrolling now · 1 studies all time

What they study most

Diffuse Large B-cell Lymphoma

Studies at this site

• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed